The paper ‘Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway’ co-authored by Quantify’s Fredrik Borgström, Amanda Hansson-Hedblom and Isabelle Axelsson, has been published in the Journal of Headache and Pain.

The study found that in people with migraine, an increase in monthly headache days is clearly related to lower QoL and higher costs, indicating considerable potential costs-savings in reducing the number of headache days. Botox reduces headache days and is a cost-effective treatment for chronic migraine in Sweden and Norway.

Read the full article here.